Lv3
250 积分 2023-04-09 加入
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
2小时前
待确认
Diagnosis and Management of Multiple Myeloma
7天前
已完结
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
10天前
已完结
Multiple myeloma
16天前
已完结
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis
17天前
已完结
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
18天前
已完结
Zevorcabtagene Autoleucel: First Approval
18天前
已完结
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
18天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
18天前
已完结
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis
18天前
已完结
皖公网安备34019202002308
